These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38765899)

  • 1.
    Vieira JO; Pesquero JB; Nazário ACP
    Breast Care (Basel); 2024 Apr; 19(2):96-105. PubMed ID: 38765899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
    Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
    Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
    Wang Y; Xu Y; Chen J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2016 Jan; 138(2):489-96. PubMed ID: 26238069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes.
    Huang L; Lang GT; Liu Q; Shi JX; Shao ZM; Cao AY
    Ann Transl Med; 2021 Feb; 9(4):301. PubMed ID: 33708928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Carcinoma Using Image-Guided Clip Placement.
    Pandurangappa V; Paruthy SB; Jamwal R; Singh A; Tanwar S; Kumar D; Pal S; Mohan SK; Das A; Trs PR
    Cureus; 2023 Oct; 15(10):e47763. PubMed ID: 38021852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
    Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients.
    Nairuz T; Bushra YU; Kabir Y
    Asian Pac J Cancer Prev; 2021 Dec; 22(12):3809-3815. PubMed ID: 34967559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
    Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
    Kim KI; Lee KH; Kim TR; Chun YS; Lee TH; Park HK
    J Breast Cancer; 2014 Mar; 17(1):40-6. PubMed ID: 24744796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differences between clinical response and pathologic response of breast cancer after neoadjuvant chemotherapy].
    Zheng S; Zhang BL; Zhang RZ; Yang JL; Zou SM; Xue LY; Luo W; Yuan YL; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):734-8. PubMed ID: 21215162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
    Thompson BM; Chala LF; Shimizu C; Mano MS; Filassi JR; Geyer FC; Torres US; de Mello GGN; da Costa Leite C
    Eur Radiol; 2022 Mar; 32(3):1663-1675. PubMed ID: 34716780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the response to neoadjuvant chemotherapy in patients with breast cancer using ultrasound scattering coefficient: A preliminary report.
    Dobruch-Sobczak K; Piotrzkowska-Wróblewska H; Klimoda Z; Secomski W; Karwat P; Markiewicz-Grodzicka E; Kolasińska-Ćwikła A; Roszkowska-Purska K; Litniewski J
    J Ultrason; 2019; 19(77):89-97. PubMed ID: 31355579
    [No Abstract]   [Full Text] [Related]  

  • 13. The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case-control study.
    Dong MJ; Wang LB; Jiang ZN; Jin M; Hu WX; Shen JG
    Onco Targets Ther; 2014; 7():1963-9. PubMed ID: 25368523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
    Bonnefoi H; Litière S; Piccart M; MacGrogan G; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Moldovan C; Bodmer A; Zaman K; Cufer T; Campone M; Luporsi E; Malmström P; Werutsky G; Bogaerts J; Bergh J; Cameron DA;
    Ann Oncol; 2014 Jun; 25(6):1128-36. PubMed ID: 24618153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
    Pereira CBL; Leal MF; Abdelhay ESFW; Demachki S; Assumpção PP; de Souza MC; Moreira-Nunes CA; Tanaka AMDS; Smith MC; Burbano RR
    Clin Breast Cancer; 2017 Jun; 17(3):188-194. PubMed ID: 28089283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
    J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Takahashi S; Sasaki K; Ishioka C
    Breast Cancer (Auckl); 2023; 17():11782234231167655. PubMed ID: 37181950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
    Subbiah S; Gopu G; Senthilkumar P; Muniasamy P
    Indian J Cancer; 2017; 54(4):652-657. PubMed ID: 30082552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
    Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.